Icatibant Sandoz (Icatibant)

Icatibant works as a selective, competitive antagonist of the bradykinin B2 receptor. By occupying this receptor on vascular endothelial cells, it prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in HAE attacks.

The dosing regimen for icatibant is determined by the prescribing clinician based on the patient’s condition, severity of the attack, and clinical guidelines. The prescriber will specify the exact amount, frequency, and duration of subcutaneous administration.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and any required import documentation.

Icatibant is a peptide‑based B2‑receptor antagonist, offering rapid symptom relief after subcutaneous injection. Unlike C1‑esterase inhibitor concentrates, which replace a deficient protein, icatibant directly blocks bradykinin activity. This difference can affect onset of action, route of administration, and suitability for patients with specific comorbidities.

Icatibant should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary temperature excursions occur, consult the product’s stability guidelines before use.

Icatibant is supplied as a sterile solution for subcutaneous injection. The prescriber will instruct the patient or caregiver on the injection site (typically the abdomen or thigh), technique, and any necessary post‑injection monitoring. No oral formulation exists.

Serious risks include hypersensitivity reactions such as rash, urticaria, or anaphylaxis, as well as paradoxical angioedema, severe hypotension, and rare cases of thrombocytopenia. Patients should seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, or a sudden drop in blood pressure.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients with severe renal impairment, those taking ACE inhibitors or neprilysin inhibitors, and pregnant or breastfeeding women unless the benefit clearly outweighs the risk.